These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 18806245)

  • 1. Valproate-induced hyperammonemic encephalopathy without cognitive sequelae: a case report in the psychiatric setting.
    Dealberto MJ; Sarazin FF
    J Neuropsychiatry Clin Neurosci; 2008; 20(3):369-71. PubMed ID: 18806245
    [No Abstract]   [Full Text] [Related]  

  • 2. [Valproate-induced hyperammonemic encephalopathy. Review of cases in the psychiatric setting].
    Fassi G; Igoa A; Liste OA
    Vertex; 2008; 19(82):371-7. PubMed ID: 19424520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of valproate-induced hyperammonemic encephalopathy: look beyond the liver.
    Alqahtani S; Federico P; Myers RP
    CMAJ; 2007 Sep; 177(6):568-9. PubMed ID: 17846437
    [No Abstract]   [Full Text] [Related]  

  • 4. Valproate-induced hyperammonemia in mental retardation: a case report and review of the literature.
    Khoo CL; Naik S; Lua R; Chai SB; Liew A; Sim K
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):561-2. PubMed ID: 20184937
    [No Abstract]   [Full Text] [Related]  

  • 5. Valproate-related hyperammonemic encephalopathy: report of 1 case.
    Selvi Y; Annagur BB; Sayin AA; Akbaba N
    J Clin Psychopharmacol; 2014 Jun; 34(3):e1. PubMed ID: 24633004
    [No Abstract]   [Full Text] [Related]  

  • 6. Valproate-induced hyperammonemic encephalopathy with normal liver function.
    Rath A; Naryanan TJ; Chowdhary GV; Murthy JM
    Neurol India; 2005 Jun; 53(2):226-8. PubMed ID: 16010067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproate-induced hyperammonemic encephalopathy associated with urinary tract infection and urinary retention in the psychiatric setting.
    Dawson LP; Lee SJ; Hollander YS
    Aust N Z J Psychiatry; 2016 Nov; 50(11):1110. PubMed ID: 27056174
    [No Abstract]   [Full Text] [Related]  

  • 8. Valproate-induced hyperammonemic encephalopathy: imaging findings on diffusion-weighted MRI.
    Grubben B; De Jonghe P; Cras P; Demey HE; Parizel PM
    Eur Neurol; 2004; 52(3):178-81. PubMed ID: 15528922
    [No Abstract]   [Full Text] [Related]  

  • 9. Valproate-associated hyperammonemic encephalopathy.
    Wadzinski J; Franks R; Roane D; Bayard M
    J Am Board Fam Med; 2007; 20(5):499-502. PubMed ID: 17823470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproate-Induced Hyperammonemic Encephalopathy in General Hospital Patients With One or More Psychiatric Disorders.
    Lewis C; Tesar GE; Dale R
    Psychosomatics; 2017; 58(4):415-420. PubMed ID: 28411969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risperidone, a risk factor for valproate-induced encephalopathy?
    Rodrigues-Silva N; Venâncio Â; Bouça J
    Gen Hosp Psychiatry; 2013; 35(4):452.e5-6. PubMed ID: 23317937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting.
    Dealberto MJ
    Int Clin Psychopharmacol; 2007 Nov; 22(6):330-7. PubMed ID: 17917551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valproate-induced encephalopathy related to concurrent antimanic medications.
    Trojak B; de la Gastine B; Dollfus S
    J Neuropsychiatry Clin Neurosci; 2011; 23(1):E22-3. PubMed ID: 21304120
    [No Abstract]   [Full Text] [Related]  

  • 14. Valproate-induced hyperammonemic encephalopathy: a case report.
    Shah S; Wang R; Vieux U
    J Med Case Rep; 2020 Jan; 14(1):19. PubMed ID: 31980035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Valproic acid in prophylaxis of bipolar disorder. A case of valproate-induced encephalopathy].
    Rottach KG; Weiss-Brummer J; Wieland U; Schmauss M
    Nervenarzt; 2000 May; 71(5):401-3. PubMed ID: 10846716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute akinetic crisis with marked cognitive impairment due to Valproate treatment.
    Reif A; Hamelbeck B; Pfuhlmann B
    Int J Geriatr Psychiatry; 2003 Apr; 18(4):356-7. PubMed ID: 12673616
    [No Abstract]   [Full Text] [Related]  

  • 17. Valproate-induced hyperammonaemia.
    Raja M; Azzoni A
    J Clin Psychopharmacol; 2002 Dec; 22(6):631-3. PubMed ID: 12454569
    [No Abstract]   [Full Text] [Related]  

  • 18. A case of valproate-induced encephalopathy.
    Hong L; Schutz J; Nance M
    Aust N Z J Psychiatry; 2012 Dec; 46(12):1200-1. PubMed ID: 22619383
    [No Abstract]   [Full Text] [Related]  

  • 19. [Inappropriate antidiuretic hormone secretion induced by sodium valproate].
    Bève E; Beck E; Pinto E; Ansseau M
    Rev Med Liege; 2010 Jan; 65(1):6-9. PubMed ID: 20222501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of valproate-induced alopecia.
    Fatemi SH; Calabrese JR
    Ann Pharmacother; 1995 Dec; 29(12):1302. PubMed ID: 8672845
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.